Cargando…
Orexin-A Reverse Bone Mass Loss Induced by Chronic Intermittent Hypoxia Through OX1R-Nrf2/HIF-1α Pathway
BACKGROUND: Recent studies suggest that there is a potential connection between obstructive sleep apnea (OSA) and osteoporosis through dysregulation of bone metabolism. Orexin-A, a neuroprotective peptide secreted by the hypothalamus, is at a lower level in the plasma of OSA patients, which regulate...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9270907/ https://www.ncbi.nlm.nih.gov/pubmed/35818538 http://dx.doi.org/10.2147/DDDT.S363286 |
_version_ | 1784744568445468672 |
---|---|
author | Gu, Hong Ru, Yiwen Wang, Wei Cai, Guanhui Gu, Lanxin Ye, Junjie Zhang, Wei-Bing Wang, Lin |
author_facet | Gu, Hong Ru, Yiwen Wang, Wei Cai, Guanhui Gu, Lanxin Ye, Junjie Zhang, Wei-Bing Wang, Lin |
author_sort | Gu, Hong |
collection | PubMed |
description | BACKGROUND: Recent studies suggest that there is a potential connection between obstructive sleep apnea (OSA) and osteoporosis through dysregulation of bone metabolism. Orexin-A, a neuroprotective peptide secreted by the hypothalamus, is at a lower level in the plasma of OSA patients, which regulates appetite, energy expenditure and sleep-wake states. However, the protective effect of orexin-A on bone metabolism in OSA is unclear. PURPOSE: To investigate whether the activation of OX1R by orexin-A can reverse bone mass loss induced by chronic intermittent hypoxia (CIH). METHODS: Mice were randomly divided into the normoxia group and CIH group. Within the CIH or normoxia groups, treatment groups were given a subcutaneous injection of either orexin-A or saline vehicle once every day for 4 weeks and then femurs were removed for micro-CT scans. Histology and immunohistochemical staining were performed to observe and calculate the changes in femurs as a result of hypoxia. Cell immunofluorescence and immunohistochemical staining were used to detect the expression of orexin receptors in MC3T3-E1 cells or in bones. CCK-8 assay, ALP assay kit and alizarin red staining were used to detect the viability, alkaline phosphatase (ALP) activity, and capacity of mineralization, respectively. The effect of orexin-A on osteogenic differentiation of MC3T3-E1 cells was evaluated using qRT-PCR, Western blot and cell staining. RESULTS: CIH led to a decrease in the amount and density of trabecular bone, downregulated OCN expression while increasing osteoclast numbers in femurs and inhibited the expression of RUNX2, OSX, OPN and Nrf2 in MC3T3-E1 cells. Orexin-A treatment alleviated these CIH-induced effects by combining to OX1R. The level of HIF-1α was elevated both in CIH and orexin-A treatment groups. CONCLUSION: CIH environment inhibits osteogenesis and orexin-A can reverse bone mass loss induced by CIH through OX1R-Nrf2/HIF-1α pathway. |
format | Online Article Text |
id | pubmed-9270907 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-92709072022-07-10 Orexin-A Reverse Bone Mass Loss Induced by Chronic Intermittent Hypoxia Through OX1R-Nrf2/HIF-1α Pathway Gu, Hong Ru, Yiwen Wang, Wei Cai, Guanhui Gu, Lanxin Ye, Junjie Zhang, Wei-Bing Wang, Lin Drug Des Devel Ther Original Research BACKGROUND: Recent studies suggest that there is a potential connection between obstructive sleep apnea (OSA) and osteoporosis through dysregulation of bone metabolism. Orexin-A, a neuroprotective peptide secreted by the hypothalamus, is at a lower level in the plasma of OSA patients, which regulates appetite, energy expenditure and sleep-wake states. However, the protective effect of orexin-A on bone metabolism in OSA is unclear. PURPOSE: To investigate whether the activation of OX1R by orexin-A can reverse bone mass loss induced by chronic intermittent hypoxia (CIH). METHODS: Mice were randomly divided into the normoxia group and CIH group. Within the CIH or normoxia groups, treatment groups were given a subcutaneous injection of either orexin-A or saline vehicle once every day for 4 weeks and then femurs were removed for micro-CT scans. Histology and immunohistochemical staining were performed to observe and calculate the changes in femurs as a result of hypoxia. Cell immunofluorescence and immunohistochemical staining were used to detect the expression of orexin receptors in MC3T3-E1 cells or in bones. CCK-8 assay, ALP assay kit and alizarin red staining were used to detect the viability, alkaline phosphatase (ALP) activity, and capacity of mineralization, respectively. The effect of orexin-A on osteogenic differentiation of MC3T3-E1 cells was evaluated using qRT-PCR, Western blot and cell staining. RESULTS: CIH led to a decrease in the amount and density of trabecular bone, downregulated OCN expression while increasing osteoclast numbers in femurs and inhibited the expression of RUNX2, OSX, OPN and Nrf2 in MC3T3-E1 cells. Orexin-A treatment alleviated these CIH-induced effects by combining to OX1R. The level of HIF-1α was elevated both in CIH and orexin-A treatment groups. CONCLUSION: CIH environment inhibits osteogenesis and orexin-A can reverse bone mass loss induced by CIH through OX1R-Nrf2/HIF-1α pathway. Dove 2022-07-05 /pmc/articles/PMC9270907/ /pubmed/35818538 http://dx.doi.org/10.2147/DDDT.S363286 Text en © 2022 Gu et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Gu, Hong Ru, Yiwen Wang, Wei Cai, Guanhui Gu, Lanxin Ye, Junjie Zhang, Wei-Bing Wang, Lin Orexin-A Reverse Bone Mass Loss Induced by Chronic Intermittent Hypoxia Through OX1R-Nrf2/HIF-1α Pathway |
title | Orexin-A Reverse Bone Mass Loss Induced by Chronic Intermittent Hypoxia Through OX1R-Nrf2/HIF-1α Pathway |
title_full | Orexin-A Reverse Bone Mass Loss Induced by Chronic Intermittent Hypoxia Through OX1R-Nrf2/HIF-1α Pathway |
title_fullStr | Orexin-A Reverse Bone Mass Loss Induced by Chronic Intermittent Hypoxia Through OX1R-Nrf2/HIF-1α Pathway |
title_full_unstemmed | Orexin-A Reverse Bone Mass Loss Induced by Chronic Intermittent Hypoxia Through OX1R-Nrf2/HIF-1α Pathway |
title_short | Orexin-A Reverse Bone Mass Loss Induced by Chronic Intermittent Hypoxia Through OX1R-Nrf2/HIF-1α Pathway |
title_sort | orexin-a reverse bone mass loss induced by chronic intermittent hypoxia through ox1r-nrf2/hif-1α pathway |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9270907/ https://www.ncbi.nlm.nih.gov/pubmed/35818538 http://dx.doi.org/10.2147/DDDT.S363286 |
work_keys_str_mv | AT guhong orexinareversebonemasslossinducedbychronicintermittenthypoxiathroughox1rnrf2hif1apathway AT ruyiwen orexinareversebonemasslossinducedbychronicintermittenthypoxiathroughox1rnrf2hif1apathway AT wangwei orexinareversebonemasslossinducedbychronicintermittenthypoxiathroughox1rnrf2hif1apathway AT caiguanhui orexinareversebonemasslossinducedbychronicintermittenthypoxiathroughox1rnrf2hif1apathway AT gulanxin orexinareversebonemasslossinducedbychronicintermittenthypoxiathroughox1rnrf2hif1apathway AT yejunjie orexinareversebonemasslossinducedbychronicintermittenthypoxiathroughox1rnrf2hif1apathway AT zhangweibing orexinareversebonemasslossinducedbychronicintermittenthypoxiathroughox1rnrf2hif1apathway AT wanglin orexinareversebonemasslossinducedbychronicintermittenthypoxiathroughox1rnrf2hif1apathway |